Long-Term Treatment of Collagenous Colitis With Budesonide

Collagenous Colitis Clinical Trial

Official title:
Long-Term Treatment of Collagenous Colitis With Budesonide. Prospective, Doubleblind Placebo-Controlled Trial.

Status Active, not recruiting

Clinical Trial Summary

The aim of the trial is to examine the effect of budesonide treatment on collagenous colitis. All patients is treated for 6 weeks with budesonide and thereafter randomised to 24 weeks treatment with placebo or continued budesonide. The end poit is effect on clinical symptoms (number of daily stools)

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00139165
Study type	Interventional
Source	Bonderup, Ole K., M.D.
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	September 2004
Completion date	March 2006

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03658993` - Rifaximin-treatment of Collagenous Colitis	Phase 3
Completed	`NCT00450086` - Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis	Phase 3
Recruiting	`NCT01504048` - Usefulness of Chromoendoscopy in Diagnosing Microscopic Colitis	N/A
Completed	`NCT01928667` - Case-Control Study to Identify Risk Factors for Microscopic Colitis	N/A
Completed	`NCT00180076` - Budesonide for Maintenance Treatment of Collagenous Colitis	Phase 3